Im Cannabis Corp (IMCC)vsNovartis AG ADR (NVS)
IMCC
Im Cannabis Corp
$0.28
+10.70%
HEALTHCARE · Cap: $1.72M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 103275% more annual revenue ($56.58B vs $54.73M). NVS leads profitability with a 23.9% profit margin vs -20.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
IMCC
Hold37
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMCC.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
17.6% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -119.8% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IMCC
The strongest argument for IMCC centers on Revenue Growth. Revenue growth of 17.6% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : IMCC
The primary concerns for IMCC are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 4.43 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
IMCC profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
IMCC carries more volatility with a beta of 2.27 — expect wider price swings.
IMCC is growing revenue faster at 17.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 37/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Im Cannabis Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?